In the last trading session, 4.0 million AbCellera Biologics Inc (NASDAQ:ABCL) shares changed hands as the company’s beta touched 0.43. With the company’s per share price at $2.96 changed hands at -$0.19 or -6.03% during last session, the market valuation stood at $874.28M. ABCL’s last price was a discount, traded about -104.39% off its 52-week high of $6.05. The share price had its 52-week low at $2.34, which suggests the last value was 20.95% up since then. When we look at AbCellera Biologics Inc’s average trading volume, we note the 10-day average is 2.59 million shares, with the 3-month average coming to 2.05 million.

Analysts gave the AbCellera Biologics Inc (ABCL) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.22. If we narrow down to specifics, the data shows that 0 out of 9 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended ABCL as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. AbCellera Biologics Inc’s EPS for the current quarter is expected to be -0.15.

AbCellera Biologics Inc (NASDAQ:ABCL) trade information

Instantly ABCL was in red as seen at the end of in last trading. With action 8.82%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -48.16%, with the 5-day performance at 8.82% in the green. However, in the 30-day time frame, AbCellera Biologics Inc (NASDAQ:ABCL) is 17.46% up. Looking at the short shares, we see there were 17.35 million shares sold at short interest cover period of 10.12 days.

The consensus price target for the stock as assigned by Wall Street analysts is 23.5, meaning bulls need an upside of 87.4% from its current market value. According to analyst projections, ABCL’s forecast low is 5 with 34 as the target high. To hit the forecast high, the stock’s price needs a -1048.65% plunge from its current level, while the stock would need to soar -68.92% for it to hit the projected low.

AbCellera Biologics Inc (ABCL) estimates and forecasts

Data shows that the AbCellera Biologics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -22.51% over the past 6 months, a -15.69% in annual growth rate that is considerably lower than the industry average of 17.10%. Year-over-year growth is forecast to reach -18.10% down from the last financial year.

Consensus estimates given by 9 financial analysts project the company’s revenue in the current quarter to hit an average of 7.12M. 2 analysts are of the opinion that AbCellera Biologics Inc’s revenue for the current quarter will be 6.43M. The company’s revenue for the corresponding quarters a year ago was 9.18M and 9.95M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -22.40%. The estimates for the next quarter sales put growth at -35.40%.

The 2024 estimates are for AbCellera Biologics Inc earnings to decrease by -12.89%, but the outlook for the next 5-year period is at 10.00% per year.

ABCL Dividends

AbCellera Biologics Inc is expected to release its next quarterly earnings report in December.

AbCellera Biologics Inc (NASDAQ:ABCL)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 27.99% of AbCellera Biologics Inc shares while 38.03% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 52.81%. There are 38.03% institutions holding the AbCellera Biologics Inc stock share, with BAKER BROS. ADVISORS LP the top institutional holder. As of 2024-06-30, the company held 9.4033% of the shares, roughly 27.53 million ABCL shares worth $81.48 million.

BAILLIE GIFFORD & CO holds the second largest percentage of outstanding shares, with 7.4852% or 21.91 million shares worth $64.86 million as of 2024-06-30.